Core Insights - The company projects adjusted EBITDA exceeding $300 million for FY26, emphasizing a focus on maximizing LINZESS, advancing apraglutide, and ensuring sustained profits and cash flows [1] - A strategic decision has been made to lower the LINZESS list price effective January 1, 2026, to adapt to changing healthcare dynamics and enhance patient access, which is expected to lead to higher net sales year-over-year [1] - The anticipated increase in net sales is attributed to the removal of the inflationary component of required rebates across various channels, including Medicaid, due to the reduced list price [1] - The company is committed to disciplined expense management, which is expected to contribute to the projected adjusted EBITDA of over $300 million in 2026 [1] - Ongoing strategic alternatives review is in progress to maximize shareholder value, with further updates expected [1]

Core Viewpoint - Atkore Inc. is expanding its strategic alternatives review to include assets beyond its core electrical infrastructure portfolio, considering options such as a potential sale or merger of the entire company to maximize shareholder value [1][2]. Strategic Review Process - The Board of Directors has authorized Citi and J.P. Morgan Securities LLC to assist in the expanded strategic review process [2]. - There is no definitive timetable for the completion of the strategic alternatives review, and the company does not intend to make further public comments until necessary [3]. Board of Directors Update - Atkore will appoint Franklin Edmonds to its Board of Directors as part of a cooperation agreement with Irenic Capital Management, expanding the Board to ten directors, with nine being independent [4][5]. - A Strategic Review Committee will be formed to oversee the evaluation of strategic alternatives, with Bruce Taten serving as a Special Advisor [4]. Management's Commitment - The CEO, Bill Waltz, will remain in his position through the conclusion of the strategic review, emphasizing the commitment to strengthen the business and improve the cost structure [2][4]. Irenic Capital Management's Role - Irenic Capital Management expresses confidence in Atkore's potential to unlock significant value and supports the Board's collaborative approach to value creation [6]. Advisory Team - Citi is the lead financial advisor, with J.P. Morgan Securities LLC also serving as a financial advisor, while Debevoise & Plimpton LLP provides legal advice [7].